Press release 📈 Stocks 🌍 United States

ImmunityBio, Geron, and TG Therapeutics Lead 2026 Deloitte Fast 500 Rankings

Deloitte's 2026 Technology Fast 500 rankings feature ImmunityBio, Geron, and TG Therapeutics among the top five fastest-growing firms, with the collective list achieving an average revenue growth rate of 1,134% between 2022 and 2025.

🕐 1 min read

4 assets impacted (Stocks). Net bias: 4 Bullish, 0 Bearish, 0 Neutral. Strongest signal: IBRX ↑ 2/10 (55% confidence).

📊 Affected Assets (4)

IBRX
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

ImmunityBio ranks 2nd on Deloitte's 2026 Technology Fast 500 with 47,103% revenue growth from 2022 to 2025. Such recognition can mildly support sentiment, but it is an award based on historical growth, not new financial guidance, so the price effect should be limited.

Catalysts
  • ▲ Named #2 on the Deloitte North America Technology Fast 500, published Nov. 18, 2026
Risk Factors
  • ▼ No new revenue figures, guidance or orders disclosed; ranking reflects 2022-2025 history
GERN
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

Geron ranks 4th on the 2026 Fast 500 with 30,753% revenue growth from 2022 to 2025 and is the fastest-growing company in the Bay Area region. This is recognition of past growth rather than new financial information, so any price effect should be modest.

Catalysts
  • ▲ Named #4 on the Deloitte North America Technology Fast 500, published Nov. 18, 2026
Risk Factors
  • ▼ Award based on historical 2022-2025 growth; no new earnings or guidance in the article
TGTX
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

TG Therapeutics ranks 5th on the 2026 Fast 500 with 22,029% revenue growth from 2022 to 2025. The award may mildly boost sentiment, but it confirms past growth only and adds no new financial data, limiting the price impact.

Catalysts
  • ▲ Named #5 on the Deloitte North America Technology Fast 500, published Nov. 18, 2026
Risk Factors
  • ▼ No current revenue, guidance or new business developments disclosed in the article
IONQ
Bullish 🤖 50%
📅 Short-term 🌍 US · Explicit

IonQ appears in the ranking as the fastest-growing company in Greater Washington, D.C., at overall rank 67. It is a passing mention without its growth rate disclosed, so the price effect should be negligible.

Catalysts
  • ▲ Named fastest-growing Greater Washington, D.C. company at rank 67 on the 2026 Fast 500
Risk Factors
  • ▼ No growth figure, revenue data or other financials given for IonQ in the article

🧭 Full analysis of these assets

🎯 Key Takeaways

  • ImmunityBio ranked 2nd on the list with a 47,103% revenue growth rate from 2022 to 2025.
  • Geron Corporation secured the 4th position with 30,753% growth, leading the Bay Area region.
  • TG Therapeutics placed 5th overall, reporting a 22,029% revenue increase over the three-year period.
  • IonQ was recognized as the fastest-growing company in the Greater Washington, D.C. market, ranking 67th overall.
  • The 2026 Fast 500 honorees achieved a combined revenue increase of more than $91 billion from 2022 to 2025.

📝 Executive Summary

Deloitte released its 2026 North America Technology Fast 500, highlighting the fastest-growing technology companies based on revenue growth from 2022 to 2025. ImmunityBio, Geron Corporation, and TG Therapeutics secured top-five spots, reporting growth rates of 47,103%, 30,753%, and 22,029% respectively.

❓ FAQ

IBRX · Does this ranking mean ImmunityBio's business is growing?

The Deloitte ranking shows the company achieved 47,103% revenue growth from 2022 to 2025, but the article provides no current or forward-looking financial figures.

GERN · Will this ranking move Geron's stock?

Probably only slightly. The article contains no new financial results, just the ranking showing 30,753% revenue growth from 2022 to 2025.

TGTX · What does the ranking say about TG Therapeutics?

It shows 22,029% revenue growth from 2022 to 2025, the 5th fastest in North America on Deloitte's list, with no other financial details given.

IONQ · How did IonQ rank on the Deloitte Fast 500?

IonQ is listed as the fastest-growing company in the Greater Washington, D.C. market, ranked 67th overall, but the article does not disclose its revenue growth rate.